Cardiff Oncology Inc

CRDF

Company Profile

  • Business description

    Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

  • Contact

    11055 Flintkote Avenue
    San DiegoCA92121
    USA

    T: +1 858 952-7570

    E: [email protected]

    https://www.cardiffoncology.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    33

Stocks News & Analysis

stocks

Undervalued ASX income play

Major development projects remain on schedule.
stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

With the monetization of GenAI, here’s what we think of Alphabet’s stock
stocks

Going into earnings, Is Meta stock a buy, a sell, or fairly valued?

With a focus on leveraging its AI investments, here’s what we think of Meta stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,941.5015.300.17%
CAC 407,763.3834.84-0.45%
DAX 4024,119.80188.00-0.77%
Dow JONES (US)44,323.0719.12-0.04%
FTSE 1009,012.390.60-0.01%
HKSE25,130.03135.890.54%
NASDAQ20,974.1878.520.38%
Nikkei 22539,774.9244.19-0.11%
NZX 50 Index12,833.74127.77-0.99%
S&P 5006,305.608.810.14%
S&P/ASX 2008,677.209.000.10%
SSE Composite Index3,581.8622.070.62%

Market Movers